Dose Insider / Glossary / SURMOUNT-3

SURMOUNT-3Tirzepatide after an intensive lifestyle program

Updated November 20, 2026 · 3 min read · Wadden et al., Nat Med 2023; ZEPBOUND label

SURMOUNT-3 tested whether tirzepatide adds to weight already lost through diet and exercise.

−18.4%Tirzepatide, further change over 72 weeks
Further change over 72 weeksAfter a 12-week lifestyle program, %Tirzepatide−18.4%Placebo+2.5%Further change over 72 weeksAfter a 12-week lifestyle program, %Tirzepatide−18.4%Placebo+2.5%

87.5% on tirzepatide lost at least 5% more, against 16.5% on placebo.

On this page

Adults first went through a 12-week intensive lifestyle program, and those who lost at least 5% of their weight, 579 people, were then assigned to tirzepatide or placebo for 72 weeks. On tirzepatide they lost a further 18.4% of their weight; on placebo they regained 2.5%. It was published in Nature Medicine in 2023.1

How the trial was run

The trial first enrolled 806 adults; 579 of them, about 72%, lost at least 5% in the 12-week program and went on to the drug phase, which makes the whole trial 84 weeks long.2 Participants had a body mass index of 30 or more, or 27 or more with at least one obesity-related complication, and did not have diabetes. Only those who reached a 5% loss in the 12-week program went on. They then received the highest dose of tirzepatide they tolerated, 10 mg or 15 mg, or a matching placebo, once a week for 72 weeks.1

The Zepbound label includes the trial as its Study 3 and describes the intensive program as a lead-in followed by a standard lifestyle intervention during the randomized part.2 The main analysis counted everyone as assigned, whether or not they kept taking the drug.1

What it found

Wadden et al., 2023.1

On the Zepbound label, 10% of people on tirzepatide in this trial stopped because of adverse reactions, against 2% on placebo.2

What it means

The trial answers a question many people ask: if diet and exercise already worked, does a medicine still help? It does. People who had lost 5% or more on their own, with intensive support, lost far more once tirzepatide was added. Those on placebo slowly regained even with continued lifestyle support. The authors' conclusion was that tirzepatide gave substantial additional weight loss in people who had already lost at least 5% with intensive lifestyle intervention.1

It also shows that the lifestyle program and the drug are not alternatives. The label approves Zepbound together with a reduced-calorie diet and more physical activity, and SURMOUNT-3 kept a standard lifestyle intervention in both groups after the lead-in.2 Our page on what to eat on a GLP-1 covers the diet side.

Next to the other SURMOUNT trials

In SURMOUNT-1, without a lifestyle lead-in, the 15 mg dose lowered weight by 20.9% over 72 weeks.3 SURMOUNT-3's 18.4% came on top of an earlier loss, so the total from before the program was larger than the drug's share alone. The trials are designed differently and the numbers are not additive in a simple way. What they share is the pattern: on placebo, weight changed little or crept back, by −3.1% in SURMOUNT-1 and +2.5% here, while on tirzepatide it kept falling through week 72.1,3

Limits

The trial only included people who succeeded in the lifestyle program, so its results do not describe those who could not lose 5% that way. It excluded people with diabetes and lasted 72 weeks after the lead-in. In the trial, 72% of those enrolled reached the 5% entry point with intensive support; how many would reach it without such a program, in everyday life, the trial does not show. ClinicalTrials.gov registration: NCT04657016.1

Sources

  1. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 2023;29:2909-2918. doi:10.1038/s41591-023-02597-w
  2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 6.1 and 14. accessdata.fda.gov
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. doi:10.1056/NEJMoa2206038

Related analyses

Log meals, activity and weight together and see what moves the needle for you.

Open Dose Insider